MERCK DRN EDMERCK DRN EDMERCK DRN ED

MERCK DRN ED

No trades
See on Supercharts

Key facts today

Merck & Company, Inc. (MRK) is pursuing approval for clesrovimab, a single-dose vaccine for infants to protect against RSV during their first season, with potential ordering availability by July 2025.
Analyze the impactAnalyze the impact
Market capitalization
‪1.56 T‬BRL
0.00BRL
‪1.82 B‬BRL
‪299.05 B‬BRL
Beta (1Y)
−0.46

About Merck & Company, Inc.


CEO
Robert M. Davis
Headquarters
Rahway
Website
Founded
1891
ISIN
BRMRCKBDR003
FIGI
BBG0019P2RN5
Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:

See all ideas 

Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
MRK5002693
Merck & Co., Inc. 2.45% 24-JUN-2050
Yield to maturity
6.74%
Maturity date
Jun 24, 2050
US58933YBF1
MERCK & CO. 21/51
Yield to maturity
6.72%
Maturity date
Dec 10, 2051
MRK5319197
Merck & Co., Inc. 2.9% 10-DEC-2061
Yield to maturity
6.67%
Maturity date
Dec 10, 2061
US58933YBA2
MERCK & CO. 20/40
Yield to maturity
6.39%
Maturity date
Jun 24, 2040
MRK3900816
Merck & Co., Inc. 3.6% 15-SEP-2042
Yield to maturity
5.98%
Maturity date
Sep 15, 2042
US58933YAT2
MERCK CO. 2045
Yield to maturity
5.98%
Maturity date
Feb 10, 2045
MRK4806294
Merck & Co., Inc. 4.0% 07-MAR-2049
Yield to maturity
5.94%
Maturity date
Mar 7, 2049
US58933YAJ4
MERCK CO. 13/43
Yield to maturity
5.80%
Maturity date
May 18, 2043
MRK.GF
Merck & Co., Inc. 5.76% 03-MAY-2037
Yield to maturity
5.70%
Maturity date
May 3, 2037
US58933YAV7
MERCK & CO. 19/39
Yield to maturity
5.67%
Maturity date
Mar 7, 2039
MRK5584755
Merck & Co., Inc. 5.0% 17-MAY-2053
Yield to maturity
5.58%
Maturity date
May 17, 2053

Explore more bonds